FDMT

4D Molecular Therapeutics Inc.

• TipRanks·03/31 00:08

  4D Molecular Therapeutics Consolidates Financial Leadership Under New Role

• Reuters·03/30 21:31

  4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

• Dow Jones·03/30 16:10

  4D Molecular Therapeutics Coverage Assumed by Jefferies at Buy

• Dow Jones·03/30 16:10

  4D Molecular Therapeutics Price Target Cut to $21.00/Share From $40.00 by Jefferies

• TipRanks·03/30 13:08

  4D Molecular assumed with a Buy at Jefferies

• Reuters·03/30 07:35

  U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

• TipRanks·03/20 12:04

  Goldman Sachs Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)

• Dow Jones·03/20 10:44

  4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

• Benzinga·03/20 10:35

  HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

• TipRanks·03/20 10:20

  Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)

• TipRanks·03/20 06:00

  Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies

• Simply Wall St·03/19 22:10

  4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative

• Dow Jones·03/19 14:13

  4D Molecular Therapeutics Price Target Raised to $35.00/Share From $32.00 by RBC Capital

• Dow Jones·03/19 14:13

  4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

• Benzinga·03/19 14:04

  RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35